Questions: Antibody Affinity and Avidity: Quantifying Antibody-Antigen Interactions

Question 1

IgM has ten antigen-binding sites but relatively low individual affinity (high Kd) for a viral surface protein. IgG has two binding sites but much higher individual affinity (low Kd). Which antibody would likely be MORE effective at binding a virus with densely clustered surface epitopes?

• A. IgG, because lower Kd always translates directly to stronger functional binding regardless of valency
• B. IgM, because ten simultaneous binding sites dramatically lower the effective off-rate — the probability that all ten sites release simultaneously approaches zero, creating very high avidity
• C. They would be equally effective because avidity and affinity always compensate for each other precisely
• D. IgG, because bivalent binding is sufficient for neutralization and additional binding sites add no functional benefit

Answer: (B)

This is the core distinction between affinity and avidity. Individual IgM sites may have modest affinity, but when ten sites engage simultaneously with a pathogen surface bearing many copies of the same epitope, the effective off-rate approaches zero — it is statistically improbable that all ten sites detach at exactly the same moment. This is why IgM is highly effective in early immune responses before affinity maturation has raised individual-site Kd values. Affinity (single-site Kd) predicts binding in monovalent systems; avidity predicts functional binding in polyvalent systems like pathogen surfaces.

Question 2

An antibody has a Kd of 10^-7 M early in an immune response. After affinity maturation in germinal centers, the Kd drops to 10^-10 M. What does this change represent?

• A. A 3-fold improvement in individual binding-site affinity (the difference between 10^-7 and 10^-10)
• B. A 1,000-fold improvement in individual binding-site affinity — the antibody now achieves half-maximal occupancy at 1,000-fold lower antigen concentration
• C. An increase in the number of antigen-binding sites per antibody molecule from two to four
• D. A shift from monovalent to bivalent interaction geometry, increasing avidity without changing per-site affinity

Answer: (B)

Kd is a concentration: it represents the antigen concentration at which half the binding sites are occupied at equilibrium. A decrease in Kd from 10^-7 M to 10^-10 M is a 1,000-fold decrease — the antibody now achieves the same level of occupancy at 1,000-fold lower antigen concentration. This represents 1,000-fold higher affinity at the individual binding site level. During affinity maturation, somatic hypermutation randomly changes residues in the variable regions, and B cells whose mutations improve complementarity with the antigen epitope are preferentially selected in germinal centers.

Question 3

An antibody with modest individual binding-site affinity can achieve very tight functional binding to a pathogen surface through avidity, because the simultaneous release of all binding sites is statistically improbable.

• T. True
• F. False

Answer: True

Avidity emerges from the multiplicative improbability of simultaneous dissociation from multiple sites. Each individual binding site has its own dissociation rate (koff), but the effective off-rate for a polyvalent interaction is the product of individual off-rates — not their sum — making simultaneous complete release vanishingly rare when multiple sites engage. This is why IgM (10 sites) can achieve effective binding strength far exceeding what its per-site Kd would predict, and why bivalent IgG binding to a viral capsid with clustered epitopes far exceeds monovalent predictions.

Question 4

Antibody serum titer — the total quantity of antibody present — is the most reliable predictor of functional potency against a pathogen.

• T. True
• F. False

Answer: False

This is a key misconception addressed by the affinity/avidity distinction. Antibodies with similar titers can have vastly different functional potency depending on their affinity (per-site Kd) and avidity (effective binding to polyvalent surfaces). High-titer low-affinity antibodies may be far less effective than low-titer high-affinity antibodies. Avidity testing — used clinically for pathogens like CMV and toxoplasma — distinguishes recent infection (low avidity) from past infection (high avidity) precisely because titer alone is insufficient. Functional potency requires characterizing both quantity and quality of binding.

Question 5

Explain why avidity is often more relevant than individual antibody affinity for predicting effectiveness against pathogens in vivo.

Model answer: In vivo, pathogens present multiple copies of surface antigens in close proximity, enabling polyvalent antibody binding. Avidity — the cumulative binding strength from simultaneous multi-site engagement — is what determines how tightly an antibody captures a pathogen under these conditions, not the Kd of a single isolated binding event. Even antibodies with modest individual Kd can achieve near-irreversible binding through avidity when many sites engage simultaneously on a pathogen surface. Additionally, avidity determines functional outcomes like neutralization and opsonization that depend on sustained, high-strength binding, not brief transient contacts. IgM's effectiveness in early immune responses despite low per-site affinity, and IgA's secretory dimeric form in mucosal immunity, both demonstrate that the immune system has evolved to exploit avidity rather than relying solely on high individual affinity.

The immune system optimizes both affinity (through somatic hypermutation and affinity maturation) and avidity (through isotype switching to multivalent formats like IgM and secretory IgA). Understanding this dual strategy explains why early IgM responses can be effective despite preceding affinity maturation, and why therapeutic antibody engineers must consider valency and epitope geometry, not just Kd.